Announcement
James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article
Posted in the last 24 hours
Fresh from the desks
Gene Editing
As Gene Therapy for Deafness Advances, the Real Question Is How It's Offered
A wave of startups in the U.S., France, and China is racing toward gene therapies for the most common genetic causes of deafness, following the FDA's April approval of the first such treatment. The science is moving fast, but it's arriving into a genuine tension between families who want it and a Deaf community with legitimate reasons for wariness.
Medicare Policy
How Medicare's Weight-Loss Drug Program Could Become Its Own Argument Against Coverage
Medicare's Bridge program offers GLP-1 weight-loss drugs for $50 a month, but a physician warns the paperwork behind that price could suppress its own usage. Low uptake caused by burdensome administration would look identical to low demand, and that manufactured verdict could be used to justify never making coverage permanent.
Credit
Why Credit-Card Delinquencies Look Worse Than They Are
The New York Fed's consumer-report delinquency measure looks alarming, but a chunk of it is stale debt banks charged off years ago that still lingers on credit reports. The rate isn't wrong, it's counting a stock of old distress as if it were a live flow of new distress.
Tax Policy
A Trump Account Is Really Two Programs, Depending on Your Income
New Treasury and IRS rules let employers put up to $2,500 tax-free into a child's Trump Account. That tax shield is worth three times as much to a top earner as a modest one, and nothing to families who owe no tax, while the account's flat $1,000 seed treats every child the same.
Credit
Cars Got Too Expensive, So Lenders Are Stretching the Loans Instead
Auto-loan originations hit a record $211 billion in Q2 2026 even as subprime delinquencies rival the Great Recession. Lenders aren't being reckless so much as absorbing an affordability problem, stretching loan terms to make an unaffordable car's monthly payment look manageable.
Medicaid Policy
Why People Who Still Qualify Keep Losing Their Medicaid
New Medicaid work requirements and twice-yearly eligibility checks take effect in 2027. The central danger isn't that ineligible people will be removed, it's that eligible people will lose coverage simply because they can't get through the paperwork, and research shows that's cheap to prevent.
Clinical Trials
The Trouble With "Targeted" Radiation: It Still Hits the Kidneys on the Way to the Tumor
Radiopharmaceuticals were pitched as precision radiation that spares healthy tissue. As more of them reach clinical trials, developers are finding the isotopes damage kidneys, livers, and bone marrow on the way to the tumor, a structural tradeoff rather than a fixable glitch.
Science Policy
Why China Is Reining In the Very Clinical-Trial System the U.S. Wants to Copy
American researchers want to copy the fast, lightly reviewed investigator-initiated trials that helped China pull ahead in biotech. China is now tightening that same system after safety and transparency problems, including a patient death. The timing is the whole story.
Pharma Supply Chain
When a Life-Sustaining Drug Depends on a Single Factory
Sanofi is running short of two enzyme-replacement drugs that Pompe disease patients depend on to stay stable, tracing to a quality bottleneck at a single Irish plant. The shortage exposes a structural fragility built into how rare-disease medicines are made, not a failing unique to one company.
B2B Research
Most Popular Research Articles
Cybersecurity Consulting Europe
Cybersecurity Consulting Services In Europe
Five names dropped out of Forrester's European evaluation between 2019 and 2021, and four of the five replacements were European firms. Regional investment turned out to be measurable and material.
Cybersecurity Consulting
Cybersecurity Consulting Services
One Leader's citation praises a private large language model, an automated evidence validation tool, and a risk scoring engine, all proprietary and built in-house. A consulting firm is being evaluated on its software.
Creative Adtech
Creative Advertising Technologies
Digital advertising spent twenty years optimizing everything except the advertisement itself. Three Forrester evaluations across six years read like a graveyard of independent vendors absorbed by bigger neighbors.
Employee Service AI
Conversational AI Platforms For Employee Services
Forrester first evaluated this market in 2019 under the heading chatbots for IT services. Its own analyst now says agentic AI is everywhere, so pick vendors who make it useful, and everywhere and useful turn out to be very different claims.
Contact Center
Contact-Center-As-A-Service Platforms
Every CCaaS vendor is selling AI that increases agent efficiency, which means fewer billable seats. They are all selling technology that shrinks their own billable base.
Connected Products
Connected Product Engineering Services
Connected products are everywhere, and Forrester's own research says far too many of them are bad. Building one well requires excellence in five disciplines that almost no single organization has all of.
CPQ
Configure, Price, Quote Solutions
In 2017 Forrester addressed this category to IT professionals. By 2023 it was addressing revenue leaders directly. The technology changed less than who was made to own it.
Commerce Media
Commerce Media Technologies
A grocery chain makes a few percent margin selling food and considerably more selling advertising to the brands whose food it sells. Forrester forecasts the category nearly doubling by 2030, right as agentic shopping threatens the human attention it depends on.
Work Management
Collaborative Work Management Tools
To even qualify for Forrester's evaluation now, a vendor needs 150 million dollars in annual product revenue. Almost every tool in this market entered organizations through a corporate card, and it is now being judged on requirements written at the top.
Announcements
News from Mavengity
Browse by topic
Where would you like to start?
Every article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Insurance
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceMortgage
Rates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgagePersonal Finance
Budgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceLegal
Contracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealthcare & Medical
Health coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareResearch
Gartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse Research
Why Mavengity
Editorial standards you can check
Independently researched
We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
Plain-English explanations
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
Straight, not slanted
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Written for readers, not lenders
Mavengity is reader-supported and editorially independent from the products we cover.